Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760952 · ClinicalTrials.gov registry record
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
A clinical trial of Neoplasms and Refractory Cancer, sponsored by Immatics US.
- Completed
- Registry status
- 242
- Enrollment target
- 4
- Study locations
NCT03760952 is a study of Neoplasms and Refractory Cancer that has completed, run by Immatics US. The registered enrollment target is 242 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03760952, a study of Neoplasms and Refractory Cancer, has completed, sponsored by Immatics US.
- COMPLETED
- Registry status
- 242 participants
- Enrollment target
- 4
- Study locations
Study Summary
This screening study will identify HLA molecular subtype positive and tumor antigen target(s) positive patients who may be eligible for enrollment into Immatics clinical studies. This screening study is intended for patients with advanced and/or metastatic solid cancers. No treatment intervention will occur as part of this screening study.
Conditions Studied
Study Locations (4)
Illinois
- University of Chicago - Chicago
New York
- Columbia University Medical Center - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- Oncology Consultants - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2022-11-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03760952
The ClinicalTrials.gov registry entry for NCT03760952 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower). The listed sponsor is Immatics US, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT03760952 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03760952 about?
NCT03760952 is a clinical study titled "Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling". This screening study will identify HLA molecular subtype positive and tumor antigen target(s) positive patients who may be eligible for enrollment into Immatics clinical studies. This screening study is intended for patients with advanced and/or metastatic solid cancers. No treatment intervention wi...
What is the current status of trial NCT03760952?
This trial is currently completed. The enrollment target is 242 participants. The study started on 2019-02-26. Estimated completion is 2022-11-15.
What conditions does trial NCT03760952 study?
This clinical trial studies the following conditions: Neoplasms, Refractory Cancer, Recurrent Cancer, Adult Solid Tumor.
Who is sponsoring clinical trial NCT03760952?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03760952 being conducted?
This trial has 4 study locations across Illinois, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.